Effects of pioglitazone on the expression of aortic VCAM-1 in rabbits fed with high-fat diets
Zhaoyu Liu
Abstract
Zhaoyu Liu
Abstract
Objective To exam the effects of Pioglitazone on the expression of aortic VCAM-1 in rabbits fed with high-fat diets. Methods Fifteen healthy male New Zealand rabbits were randomly divided into three groups to receive 8 weeks of normal diet (control group, n=5), high cholesterol diet (high-cholesterol group, n=5) or high cholesterol diet plus 3 mg·kg·d-1 pioglitazone added from the fourth week of cholesterol diet (pioglitazone treatment group, n=5). The pathomorphology of rabbit aorta was studied with haematoxylin-eosin staining, and expression of VCAM-1 in rabbit aorta detected using immunohistochemistry. Results Pioglitazone appeared to decrease intimal hyperplasia and smooth muscle cell proliferation in aorta of rabbits fed with high-cholesterol diet. Furthermore, pioglitazone significantly improved the level of high density lipoprotein but showed no effects on TG, TC and LDL-C. Expression of aortic VCAM-1 was also markedly reduced with Pioglitazone treatment as compared with rabbits on high-fat diet alone (0.42±0.11 vs 0.78±0.16,P0.01). Conclusion Pioglitazone may inhibit the upregulation of VCAM-1 in aorta of hypercholesterolemic rabbits, possibly resulting from its effects on nucleus transcription factors. These findings provide new insights into a potentially novel anti-atherosclerotic pathway by thiazolidinediones.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To exam the effects of Pioglitazone on the expression of aortic VCAM-1 in rabbits fed with high-fat diets. Methods Fifteen healthy male New Zealand rabbits were randomly divided into three groups to receive 8 weeks of normal diet (control group, n=5), high cholesterol diet (high-cholesterol group, n=5) or high cholesterol diet plus 3 mg·kg·d-1 pioglitazone added from the fourth week of cholesterol diet (pioglitazone treatment group, n=5). The pathomorphology of rabbit aorta was studied with haematoxylin-eosin staining, and expression of VCAM-1 in rabbit aorta detected using immunohistochemistry. Results Pioglitazone appeared to decrease intimal hyperplasia and smooth muscle cell proliferation in aorta of rabbits fed with high-cholesterol diet. Furthermore, pioglitazone significantly improved the level of high density lipoprotein but showed no effects on TG, TC and LDL-C. Expression of aortic VCAM-1 was also markedly reduced with Pioglitazone treatment as compared with rabbits on high-fat diet alone (0.42±0.11 vs 0.78±0.16,P0.01). Conclusion Pioglitazone may inhibit the upregulation of VCAM-1 in aorta of hypercholesterolemic rabbits, possibly resulting from its effects on nucleus transcription factors. These findings provide new insights into a potentially novel anti-atherosclerotic pathway by thiazolidinediones.
Key concepts: Pioglitazone, Internal medicine, Endocrinology, Aorta, Medicine, Cholesterol, Intimal hyperplasia, Diabetes mellitus